VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year

Deep News

10/06

VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million.

According to VISEN PHARMA's prospectus, the company's most advanced development project is lonapegsomatropin (long-acting growth hormone). The company expects to receive domestic approval for listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company possesses two unique products: nafarelin peptide and parolpatriptide, with the latter expected to submit its listing application by the end of 2025.

In June this year, VISEN PHARMA partnered with WuXi Biologics to advance localized production, striving to meet domestic patients' clinical needs with high-value products at competitive prices. In July, VISEN also established a partnership with AncoGen to jointly advance product commercialization, making future market prospects worth anticipating.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1188705635"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188705635\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188705635?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-06 11:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188705635","market":"sg","top_or_hot":-1,"title":"VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year","media":"Deep News","content":"<p>VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million.</p>\n<p>According to VISEN PHARMA's prospectus, the company's most advanced development project is lonapegsomatropin (long-acting growth hormone). The company expects to receive domestic approval for listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company possesses two unique products: nafarelin peptide and parolpatriptide, with the latter expected to submit its listing application by the end of 2025.</p>\n<p>In June this year, VISEN PHARMA partnered with WuXi Biologics to advance localized production, striving to meet domestic patients' clinical needs with high-value products at competitive prices. In July, VISEN also established a partnership with AncoGen to jointly advance product commercialization, making future market prospects worth anticipating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B Surges Over 3% in Morning Trading as Long-Acting Growth Hormone Awaits Approval This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-10-06 11:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million.</p>\n<p>According to VISEN PHARMA's prospectus, the company's most advanced development project is lonapegsomatropin (long-acting growth hormone). The company expects to receive domestic approval for listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company possesses two unique products: nafarelin peptide and parolpatriptide, with the latter expected to submit its listing application by the end of 2025.</p>\n<p>In June this year, VISEN PHARMA partnered with WuXi Biologics to advance localized production, striving to meet domestic patients' clinical needs with high-value products at competitive prices. In July, VISEN also established a partnership with AncoGen to jointly advance product commercialization, making future market prospects worth anticipating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维升药业-B","start_time":0,"source_url":"","article_id":"1188705635","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188705635","pubTimestamp":1759722636,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million. According to VISEN PHARMA's prospectus, the company's most...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维升药业-B","BK1161":"生物科技"},"translate_title":"由于长效生长激素等待今年批准，VISEN PHARMA-B早盘飙升逾3%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN PHARMA-B (02561) saw its share price climb 3.08% during morning trading, reaching HK$44.80 with a turnover of HK$1.042 million.\nAccording to VISEN PHARMA's prospectus, the company's most advanced development project is lonapegsomatropin (long-acting growth hormone). The company expects to receive domestic approval for listing in the second half of 2025, potentially becoming the third long-acting growth hormone to be marketed domestically. Currently, the company possesses two unique products: nafarelin peptide and parolpatriptide, with the latter expected to submit its listing application by the end of 2025.\nIn June this year, VISEN PHARMA partnered with WuXi Biologics to advance localized production, striving to meet domestic patients' clinical needs with high-value products at competitive prices. In July, VISEN also established a partnership with AncoGen to jointly advance product commercialization, making future market prospects worth anticipating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}